{"id":41243,"date":"2025-09-12T15:15:27","date_gmt":"2025-09-12T07:15:27","guid":{"rendered":"https:\/\/flcube.com\/?p=41243"},"modified":"2025-09-12T15:15:28","modified_gmt":"2025-09-12T07:15:28","slug":"guangzhous-bio%e2%80%91thera-solutions-secures-5-4-million-milestone-from-intas-pharma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41243","title":{"rendered":"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma"},"content":{"rendered":"\n<p><strong>Bio-Thera Solutions Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>)<\/strong> announced today that it has received a <strong>$5.4\u202fmillion milestone payment<\/strong> from <strong>Intas Pharmaceuticals Ltd.<\/strong> under a licensing and commercialization agreement signed on February\u202f10\u202f,\u202f2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusivity<\/strong> \u2013 Intas, via its U.S. subsidiary <strong>Accord BioPharma Inc.<\/strong>, holds the exclusive rights to commercialize <strong>BAT2506 (golimumab)<\/strong> in the United States.<\/li>\n\n\n\n<li><strong>Roles<\/strong> \u2013 Bio\u2011Thera will continue to conduct R&amp;D, manufacture, and supply the product; Intas will manage all U.S. commercial activities.<\/li>\n\n\n\n<li><strong>Financial Scope<\/strong> \u2013 The partnership could yield up to <strong>$164.5\u202fmillion<\/strong> in total upfront and milestone payments, comprising a <strong>$21\u202fmillion<\/strong> upfront fee and up to <strong>$143.5\u202fmillion<\/strong> in milestones. Bio\u2011Thera also stands to earn a double\u2011digit percentage of net U.S. sales.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<p>BAT2506 has already received marketing\u2011application approvals from the <strong>National Medical Products Administration (NMPA)<\/strong> in China, the <strong>U.S. Food and Drug Administration (FDA)<\/strong>, and the <strong>European Medicines Agency (EMA)<\/strong>, positioning the drug for a global launch.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Bio\u2011Thera<\/strong> \u2013 The milestone confirms the commercial viability of its golimumab platform and underscores the company\u2019s ability to secure high\u2011value partnerships.<\/li>\n\n\n\n<li><strong>For Intas<\/strong> \u2013 The deal expands its portfolio in the competitive U.S. biologics market, leveraging Intas\u2019s distribution network and Accord BioPharma\u2019s commercialization expertise.<\/li>\n\n\n\n<li><strong>Market Outlook<\/strong> \u2013 With an established regulatory footing and a robust financial framework, BAT2506 is poised to capture significant market share in the rheumatology and inflammatory\u2011disease segments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688177_20250912_A9TD.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688177_20250912_A9TD.\"><\/object><a id=\"wp-block-file--media-bf066e9b-978d-4197-bcd9-c62ad785005b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688177_20250912_A9TD.pdf\">688177_20250912_A9TD<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688177_20250912_A9TD.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bf066e9b-978d-4197-bcd9-c62ad785005b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4\u202fmillion milestone payment&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41246,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[4347,289,1259,1055],"class_list":["post-41243","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-accord-biopharma","tag-bio-thera-solutions","tag-intas-pharmaceuticals","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4\u202fmillion milestone payment from Intas Pharmaceuticals Ltd. under a licensing and commercialization agreement signed on February\u202f10\u202f,\u202f2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41243\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4\u202fmillion milestone payment from Intas Pharmaceuticals Ltd. under a licensing and commercialization agreement signed on February\u202f10\u202f,\u202f2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41243\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-12T07:15:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-12T07:15:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1205.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma\",\"datePublished\":\"2025-09-12T07:15:27+00:00\",\"dateModified\":\"2025-09-12T07:15:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1205.webp\",\"keywords\":[\"Accord BioPharma\",\"Bio-Thera Solutions\",\"Intas Pharmaceuticals\",\"SHA: 688177\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41243#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41243\",\"name\":\"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1205.webp\",\"datePublished\":\"2025-09-12T07:15:27+00:00\",\"dateModified\":\"2025-09-12T07:15:28+00:00\",\"description\":\"Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4\u202fmillion milestone payment from Intas Pharmaceuticals Ltd. under a licensing and commercialization agreement signed on February\u202f10\u202f,\u202f2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41243\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1205.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1205.webp\",\"width\":1080,\"height\":608,\"caption\":\"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41243#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma - Insight, China&#039;s Pharmaceutical Industry","description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4\u202fmillion milestone payment from Intas Pharmaceuticals Ltd. under a licensing and commercialization agreement signed on February\u202f10\u202f,\u202f2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41243","og_locale":"en_US","og_type":"article","og_title":"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma","og_description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4\u202fmillion milestone payment from Intas Pharmaceuticals Ltd. under a licensing and commercialization agreement signed on February\u202f10\u202f,\u202f2025.","og_url":"https:\/\/flcube.com\/?p=41243","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-12T07:15:27+00:00","article_modified_time":"2025-09-12T07:15:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1205.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41243#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41243"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma","datePublished":"2025-09-12T07:15:27+00:00","dateModified":"2025-09-12T07:15:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41243"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41243#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1205.webp","keywords":["Accord BioPharma","Bio-Thera Solutions","Intas Pharmaceuticals","SHA: 688177"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41243#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41243","url":"https:\/\/flcube.com\/?p=41243","name":"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41243#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41243#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1205.webp","datePublished":"2025-09-12T07:15:27+00:00","dateModified":"2025-09-12T07:15:28+00:00","description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4\u202fmillion milestone payment from Intas Pharmaceuticals Ltd. under a licensing and commercialization agreement signed on February\u202f10\u202f,\u202f2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41243#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41243"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41243#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1205.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1205.webp","width":1080,"height":608,"caption":"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41243#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Guangzhou\u2019s Bio\u2011Thera Solutions Secures $5.4\u202fMillion Milestone from Intas Pharma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1205.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41243"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41243\/revisions"}],"predecessor-version":[{"id":41247,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41243\/revisions\/41247"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41246"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}